(Q43711805)

English

Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.

scientific article published on 6 March 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Ting Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Yufei Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Liang Qiao

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Youchun Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Xueling Wu

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Dongsheng Fan

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Qinglin Peng

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Xuemei Xu

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

0 references

publication date

6 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3479-3487

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Human papillomavirus type distribution in women from Asia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

HPV Vaccines: today and in the Future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

The role of T cell antagonism and original antigenic sin in genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Efficient intracellular assembly of papillomaviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Role of Conformational Epitopes Expressed by Human Papillomavirus Major Capsid Proteins in the Serologic Detection of Infection and Prophylactic Vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Antigenic competition in a multivalent foot rot vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Prophylactic DNA immunization against multiple papillomavirus types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Immunological parameters associated with antigenic competition in a multivalent footrot vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Multiple whole bacterial antigens in polyvalent vaccine may result in inhibition of specific responses in rainbow trout (Oncorhynchus mykiss).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

The effects of antigenic competition on the efficacy of multivalent footrot vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.057

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.02.057

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43711805&oldid=2102753449"